Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure

Cardiology Journal

Volumn 16, Issue 6, 2009, Pages 545-552

  Tarquini, Roberto ^a   Guerra, Cristina Tosti ^a   Porciani, Maria Cristina ^a   Michelucci, Antonio ^a   Padeletti, Margherita ^b   Ricciardi, Giuseppe ^a   Chiostri, Marco ^a   Jelic, Sania ^c   Padeletti, Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

Heart failure; Neuro hormonal pattern; Resynchronization therapy

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; NORADRENALIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 74249085407     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med, 2001; 344: 873-880.
2. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol, 2005; 95: 17C-23C.
3. Rubaj A, Rucinski P, Rejdak K et al. Biventricular versus right ventricular pacing decreases immune activation and augments nitric oxide production in patients with chronic heart failure. Eur J Heart Fail, 2006; 8: 615-620.
4. Theodorakis GN, Flevari P, Kroupis C et al. Anti-infammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing Clin Electrophysiol, 2006; 29: 255-261.
5. Boriani G, Regoli F, Saporito D et al. Neurohormones and infammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides, 2006; 27: 1776-1786.
6. Michelucci A, Ricciardi G, Sofi F et al. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. J Card Fail, 2007; 13: 207-210.
7. Yu CM, Bleeker GB, Fung JWH et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation, 2005; 112: 1580-1586.
8. Lang RM, Bierig M, Devereux RB et al Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr, 2005; 18: 1440-1463.
9. Lilli A, Ricciardi G, Porciani MC et al Cardiac resynchronization therapy: Gender related differences in left ventricular reverse remodeling. Pacing Clin Electrophysiol, 2007;30: 1349-1355.
10. Kindermann M, Frolhig G, Doerr T, Schieffer H. Optimizing the AV delay in DDD pacemaker patients with high degree AV block: Mitral valve Doppler versus impedance cardiography. Pacing Clin Electrophysiol, 1997; 20: 2453-2462.
11. Porciani MC, Dondina C, Macioce R et al. Echocardiographic examination of atrioventricular and interventricular delay optimization in cardiac resynchronization therapy. Am J Cardiol, 2005; 95: 1108-1110.
12. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: Mediators and mechanisms. AACN Adv Crit Care, 2008; 19: 364-385.
13. Aras O, Messina SA, Shirani J, Eckelman WC, Dilsizian V. The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure. Curr Cardiol Rep, 2007; 9: 150-158.
14. Neri Serneri GG, Boddi M, Modesti PA et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res, 2001; 89: 977-982.
15. Neri Serneri GG, Boddi M, Coppo M et al. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation, 1996; 94: 1886-1893.
16. Tamura T, Furukawa Y, Taniguchi R et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J, 2007; 71: 623-630.
17. Tarquini R, Lazzeri C, Laffi G, Gensini GF. Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med, 2007; 2: 165-176.
18. Takano H, Obata JE, Kodama Y et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol, 2009; 132: 221-226.
19. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001; 86: 1930-1935.
20. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension, 2003; 42: 76-81.
21. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation, 2002; 105: 2893-2898.
22. Baratta R, Amato S, Degano C et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: Evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab, 2004; 89: 2665-2671.
23. Hotta K, Kiura K, Tabata M et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Artioscler Thromb Vasc Biol, 2000; 20: 1595-1599.
24. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation, 1999; 100: 2473-2476.
25. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 2005; 112: 1756-1762.
26. Tsutamoto T, Tanaka T, Sakai H et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J, 2007; 28: 1723-1730.
27. Tanaka T, Tsutamoto T, Nishiyama K et al. Impact of oxidative stress on plasma adiponectin in patients with chronic heart failure. Circ J, 2008; 72: 563-568.
28. Molon G, Adamo E, De Ferrari GM et al. Effects of cardiac resynchronization therapy on insulin-like growth factor-1 in patients with advanced heart failure. J Cardiovasc Med (Hagerstown), 2007; 8: 917-922.
29. Brink M, Wellen J, Delafontaine. Angiotensin II cause weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest, 1996; 97: 2509-2516
30. Corbalan R, Acevedo M, Godoy I, Jalil J, Campusano C, Klassen J. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail, 1998; 4: 115-119.
31. Vasan RS, Sullivan LM, D'Agostino RB et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med, 2003; 139: 642-648.
32. Kaplan RC, McGinn AP, Pollak MN et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab, 2007; 92: 1319-1325.
33. Johnsen SP, Hundborg HH, Sørensen HT et al. Insulin-like growth factor (IGF)-I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab, 2005; 90: 5937-5941.
34. Colao A. The GH-IGF-I axis and the cardiovascular system: Clinical implications. Clin Endocrinol (Oxford), 2008; 69: 347-358
35. Al-Obaidi MK, Hon JK, Stubbs PJ et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J, 2001; 142: E10.
36. Lellouche N, De Diego C, Cesario DA et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol, 2007; 99: 242-246.
37. Uretsky BF,, Thygesen K,, Daubert JC et al. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: Results of the CARE-HF trial. J Card Fail, 2008; 14: 670-675.
38. Sanderson JE. Echocardiography for cardiac resynchronization therapy selection: fatally flawed or misjudged? J Am Coll Cardiol, 2009; 53: 1960-1964.
39. Hawkins NM, Petrie MC, Burgess MI, McMurray JJV. Selecting patients for cardiac resynchronization therapy: The fallacy of echocardiographic dyssynchrony. J Am Coll Cardiol, 2009; 53: 1944-1959.
40. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation, 2008; 117: 2608-2616.
41. Bax JJ, Gorcsan J 3rd. Echocardiography and noninvasive imaging in cardiac resynchronization therapy: Results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) study in perspective. J Am Coll Cardiol, 2009; 53: 1933-1943.
42. Ypenburg C, van Brommerl RJ, Borleffs JW et al. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll Cardiol, 2009; 53: 483-490.